On ECHEMI
Home > Drugs > Huangshi Lishizhen Pharmaceutical Group Wuhan Lishizhen Pharmaceutical Co., Ltd.
Huangshi Lishizhen Pharmaceutical Group Wuhan Lishizhen Pharmaceutical Co., Ltd.
  • Founded in:

    2001-09-25
  • Country:

    China China
  • Address:

    Guannan Industrial Park, Wuhan East Lake New Technology Development Zone
  • Tax NO.:

    914201007310641045
  • Registered Funds:

    26 million yuan
  • Email:

Related Drugs
Ethylenediamine diacetate for injection
Ethylenediamine diacetate.
Name Description Content CAS NO. Registered Holders
Clotrimazole

1. Inhibit plasminogen activators, so that plasminogen cannot be activated into plasmin, thereby inhibiting the dissolution of fibrin and producing a hemostatic effect; 2. Promote the release of active substances by platelets, enhance platelet aggregation and adhesion, shorten coagulation time, and produce a hemostatic effect; 3. Enhance capillary resistance, reduce capillary permeability, and thus reduce bleeding.

More

1. Inhibit plasminogen activators, so that plasminogen cannot be activated into plasmin, thereby inhibiting the dissolution of fibrin and producing a hemostatic effect; 2. Promote the release of active substances by platelets, enhance platelet aggregation and adhesion, shorten coagulation time, and produce a hemostatic effect; 3. Enhance capillary resistance, reduce capillary permeability, and thus reduce bleeding.

0
Calcium folinate for injection
The main ingredient of this product is calcium folinate, and its chemical name is: N-[4-[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-10-pteridinyl)methyl]amino]benzoyl-L-glutamic acid calcium salt pentahydrate
Name Description Content CAS NO. Registered Holders
Calcium folinatc

This product is a formyl derivative of tetrahydrofolate, mainly used for the rescue of high-dose methotrexate and other folic acid antagonists. It limits the degree of damage to normal cells by methotrexate and can reverse the reaction of methotrexate to the bone marrow and gastrointestinal mucosa, but has no significant effect on the neurotoxicity caused by methotrexate that has already occurred.

More

This product is a formyl derivative of tetrahydrofolate, mainly used for the rescue of high-dose methotrexate and other folic acid antagonists. It limits the degree of damage to normal cells by methotrexate and can reverse the reaction of methotrexate to the bone marrow and gastrointestinal mucosa, but has no significant effect on the neurotoxicity caused by methotrexate that has already occurred.

6035-45-6 6
Ethylenediamine diacetate injection
Name Description Content CAS NO. Registered Holders
Clotrimazole

(1) Inhibit plasminogen activators, preventing plasminogen from activating into plasmin, thereby inhibiting the dissolution of fibrin and producing a hemostatic effect. (2) Promote the release of active substances from platelets, enhance platelet aggregation and adhesion, shorten coagulation time, and produce a hemostatic effect. (3) Enhance capillary resistance and reduce capillary permeability, thereby reducing bleeding.

More

(1) Inhibit plasminogen activators, preventing plasminogen from activating into plasmin, thereby inhibiting the dissolution of fibrin and producing a hemostatic effect. (2) Promote the release of active substances from platelets, enhance platelet aggregation and adhesion, shorten coagulation time, and produce a hemostatic effect. (3) Enhance capillary resistance and reduce capillary permeability, thereby reducing bleeding.

0
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.